Your account is not claimed yet. You can sign up with ORCID to claim your account.

Ozge Akbulut (Ozge Akbulut Caliskan)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Capillary Electrophoresis

Histone Deacetylase

Epidermal Growth Factor Receptor

Top Venues

Cell death and differentiation

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ozge Saatci, Ozge Akbulut, Metin Cetin, Vitali Sikirzhytski, Meral Uner, Deniz Lengerli, Elizabeth C O'Quinn, Martin J Romeo, Burcu Caliskan, Erden Banoglu, Sercan Aksoy, Aysegul Uner, Özgür Sahin
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. Cell death and differentiation (2023)
Esra Cicek, Ayca Circir, Merve Oyken, Ozge Akbulut, Didem Naz Dioken, Sezen Guntekin Ergun, Rengul Cetin-Atalay, Aysegul Sapmaz, Huib Ovaa, Özgür Sahin, Ayse Elif Erson-Bensan
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers. Oncogene (2021)
Ozge Akbulut, Deniz Lengerli, Ozge Saatci, Elif Duman, Urartu Özgür Şafak Şeker, Aynur Isik, Aytekin Akyol, Burcu Caliskan, Erden Banoglu, Özgür Sahin
A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate. Molecular cancer therapeutics 19 (6) (2020)
Ozge Saatci, Aysegul Kaymak, Umar Raza, Pelin Gulizar Ersan, Ozge Akbulut, Carolyn E Banister, Vitali Sikirzhytski, Unal Metin Tokat, Zaliha Gamze Aykut, Suhail A Ansari, Hayriye Tatli Dogan, Mehmet Dogan, Pouria Jandaghi, Aynur Isik, Fatma Gündoğdu, Kemal Kosemehmetoglu, Omer Dizdar, Sercan Aksoy, Aytekin Akyol, Aysegül Uner, Phillip J Buckhaults, Yasser Riazalhosseini, Özgür Sahin
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature communications 11 (1) (2020)